← Oncology Approval Tracker

FDA DECISION ·

Cabometyx

cabozantinib · Exelixis

FDA approvalNew or expanded indicationPancreatic and extra-pancreatic neuroendocrine tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children age 12 years or older with previously treated, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic.

LAMPGEN ANALYSIS

Why it matters

The CABINET study evaluated separate pancreatic and extra-pancreatic cohorts under the same kinase inhibitor program.

What research teams should watch

Record the primary tumor site and differentiation and map dose modifications to the applicable formulation and age group.

PRIMARY RECORDS

Sources